Nextensa NV/SA : Information on the total number of voting rights and shares
PRESS RELEASE
REGULATED INFORMATION
Brussels, 30 June 2022 – 5.40 PM CEST
Nextensa NV/SA : Information on the total number of voting rights and shares
In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nextensa NV (the “Company”) publishes the following information following a request for dematerialisation of registered shares (with double voting rights):
Situation as at 30 June 2022:
- Total share capital: EUR 109,997,148.34
- Total number of securities carrying voting rights: 10,002,102
- Number of securities with double voting rights: 1,797,268(1)
Total number of voting rights (= denominator) : 11,799,370
On the basis of this information, the shareholders of the Company can verify whether they are above or below one of the thresholds of 3% (threshold set by the articles of association), 5%, 10%, and so on (in multiples of five) of the total voting rights, and whether there is therefore an obligation to notify the company that they have exceeded this threshold.
(1) 204 of these 1,797,268 shares giving the right to double voting rights in principle are held by a subsidiary of the Company. The voting rights attached to these 204 shares have therefore been suspended
For more information
Michel Van Geyte,
Chief Executive Officer
+32 3 238 98 77
michel.van.geyte@nextensa.eu
About Nextensa
Nextensa NV/SA (previously named Leasinvest Real Estate) is a mixed property investor and developer since 19 July 2021. The company’s investment portfolio, which is spread over the Grand Duchy of Luxembourg (46%), Belgium (41%) and Austria (13%), had a total value on 31/03/2022 of approximately €1.34 billion. Nextensa is one of Luxembourg’s biggest property investors. The development portfolio is spread over the Tour & Taxis (B) and Cloche d’Or (L) sites, where mixed (residential and office) developments are ongoing and new sub-projects will be launched in the coming years. In addition, there is also a development pipeline in Belgium and Luxembourg of more than 300,000 m² of offices and residential real estate. The company is listed on Euronext Brussels and it has a market capitalisation of € 560.1 million (value on 29/06/2022).
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Hoylu AB: Continued SaaS growth in July15.8.2022 08:30:00 CEST | Press release
Stockholm, Sweden, August 15, 2022 – Hoylu, a leader in visual collaboration solutions for distributed teams, today announced Annual Recurring Revenue (“ARR”) as of the end of July 2022. ARR, including long term mobile contracts, reached MSEK 48.5 as of the end of July 2022, up from MSEK 46.2 as of the end of June 2022. The report for July 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information, please contact: Truls Baklid, CEO, +47 924 38 900 Email: tob@hoylu.com Karl Wiersholm, CFO, +1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu's Adaptive Workspace opens up a new way for teams to plan, build and engage --so they get the impact they want no matter the industry, department or time. Whatever your management or planning style, Hoylu fits the way you structure your team and integrates all the productivity tools you're already using. So, you easily plan and complete any project
Expereo acquires Breeze Networks, further enhancing its SD-WAN/SASE practice and presence in the UK market15.8.2022 08:00:00 CEST | Press release
AMSTERDAM, Aug. 15, 2022 (GLOBE NEWSWIRE) -- The world’s leading provider of managed network solutions, Expereo, has announced the acquisition of Breeze Networks, a managed service provider of SD-WAN/SASE technologies. The acquisition fuels Expereo’s growth trajectory, further enhancing its SD-WAN/SASE practice, building on its expanding range of services to manage SD-WAN solutions at scale to partners and multinational enterprise customers across the globe. This latest acquisition solidifies Expereo’s ambition to complement its managed network solutions with world-class advisory practice providing guidance to organizations on their global transformation to software-defined and internet-based networking. With the full support of majority investor Vitruvian Partners and minority investor Apax Partners SAS, Expereo intends to continue its acquisition strategy. Breeze Networks is a managed service provider of cloud-based (SD-WAN) network connectivity and security solutions for enterprises
DNO Releases 2021 Corporate Social Responsibility Report15.8.2022 08:00:00 CEST | Press release
Oslo, 15 August 2022 – DNO ASA, the Norwegian oil and gas operator, today released its 2021 Corporate Social Responsibility Report. The report is attached as a downloadable file and is also available on the Company's website www.dno.no. – For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2021 CSR report
Sampo plc’s share buybacks 12/08/202215.8.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 15/08/2022 at 08:30 am Sampo plc’s share buybacks 12/08/2022 On 12/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,42245.06AQEU29,72844.98CEUX9,01645.09TQEX76,83445.02XHELTOTAL130,00045.02 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 6,194,495 Sampo A shares representing 1.16 per cent of the total number of shares in Sampo plc. Details of ea
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer15.8.2022 07:15:00 CEST | Press release
Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1 Findings will be presented at an upcoming medical meeting Novartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancer Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo1. No unexpected safety signals were observed.1 Findings from the trial will be presented at an upcoming medical meeting. “We made an investment in the CANOPY program based on signals of reduced lung cancer incidence and mortality observed in the CANTOS s